Overall, these human preclinical assays demonstrate that disruption of LCOR and ERα interactions reconfigured HR+ tumor immunity toward high immune reactivity and posit the molecular targeting of ERα-LCOR interactions as a potential immune-based therapy in HR+ BC tumors. This evidence concerns the gene ESR1 and breast cancer.